MMMai M. Morsy

Mai M. Morsy

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Mai M. Morsy has a total of 31 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Unveiling the landscape of systemic sclerosis in Egypt: a comprehensive national multicenter analysis of the Egyptian EUSTAR cohort

    by Yasser El Miedany, Maha Elgaaary, Mary Wadie, Waleed Hassan, Mohamed H. Abu Zaid, Samar Abdelhamed Tabra, Sherif Ismail, Nihal Fathy, Eiman Soliman, Mai M. Morsy, et al.

    Background and objectives: Systemic sclerosis (SSc) is a heterogeneous and debilitating multi-system autoimmune disease characterized by widespread microvascular vasculopathy and progressive multi-organ fibrosis. While localized cohorts have been described, there is a critical need for a standardized, national-scale multicenter validation to fully capture the epidemiological and phenotypic characteristics of SSc in Egypt. This study aimed to delineate the nationwide clinical, serological, and functional landscape of systemic sclerosis across Egypt utilizing the standardized EUSTAR registry framework across major geographic referral centers. Methods: A multi-center, retrospective registry-based review was conducted on 354 Egyptian SSc patients enrolled within the international EUSTAR database. Longitudinal and cross-sectional data were extracted across standardized registry parameters, including detailed demographics, clinical subsets (LeRoy criteria), comprehensive organ system involvement (evaluated via high-resolution computed tomography [HRCT], echocardiography, and nailfold capillaroscopy [NFC]), autoantibody profiles, and patient-reported quality-of-life indices (HAQ-DI and L-PF questionnaires). Results: The cohort demonstrated a prominent female predominance (89.3%) with a mean overall age of disease onset of 37.6 + 13.5 years. Limited cutaneous SSc was the most frequent phenotype (53.1%), though an exceptionally high rate of diffuse cutaneous SSc was documented (42.2%). Marked microvascular severity was evidenced by a high prevalence of active digital ulcers (56.7%), a history of digital gangrene (10.8%), and a dominant “active” capillaroscopic microangiopathy pattern (47.8%). Visceral organ involvement was highly pervasive: gastrointestinal reflux and dysphagia affected 78.7% and 75.4% of patients, respectively, while Gastric Antral Vascular Ectasia (GAVE) was remarkably frequent at 20.9%. Objective interstitial lung disease (ILD) was confirmed on HRCT in 46.8% of evaluated patients ( n = 47/101), with ground-glass opacification documented in 70.4%, and an echocardiographic high probability of pulmonary hypertension (PH) was documented in 11.8% ( n = 40/342 valid cases). Serological evaluation revealed a highly robust seropositive footprint with elevated rates of anti-Scl70 (51.0%) and anti-centromere (55.6%) autoantibodies. Symptomatic inflammatory arthritis was reflected by a moderate mean disease activity index (DAS28-ESR: 4.4 + 1.3). Conclusion: The national Egyptian SSc phenotype is characterized by an significant microvascular burden, an elevated diffuse cutaneous subset rate, and widespread gastrointestinal and active inflammatory pulmonary involvement. The cohort exhibits a unique serological signature featuring highly robust autoantibody positivity and significant systemic inflammation, highlighting the urgent need for targeted national screening algorithms and specialized therapeutic access.

  • Open Access

    Real-World Effectiveness and Safety of Anifrolumab in Egyptian Patients with Moderate-to-Severe Systemic Lupus Erythematosus: A Retrospective Multicenter Study

    by Samar Tharwat, Samah A. El Bakry, Shereen Abdelsalam Olwan, Fatma Fayed, Enas S. Zahran, Maie Helal, Mai M. Morsy, Abeer Abdelmonem Shahba, Rehab Elnemr, Nehad Mohamed Elshatby, et al.

    Background and Objectives: Real-world data on anifrolumab in Egyptian patients with moderate-to-severe systemic lupus erythematosus (SLE) remain limited. This study aimed to evaluate the real-world effectiveness and safety of anifrolumab in Egyptian patients with moderate-to-severe SLE. Materials and Methods: This retrospective, multicenter, observational cohort study reviewed the medical records of 80 adults with moderate-to-severe SLE who had received at least 6 doses (≥20 weeks) of intravenous anifrolumab 300 mg every 4 weeks as part of routine clinical care at 13 Egyptian tertiary rheumatology centers; medical record review and data extraction were performed between May and July 2026. Outcomes were assessed at baseline and final follow-up and included disease activity, lupus low disease activity state (LLDAS), glucocorticoid use, flare status, laboratory parameters, and adverse events. Results: Patients were predominantly female (98.8%), with a mean age of 30.4 ± 9.8 years. Disease activity improved, with SLEDAI-2K decreasing from 11 to 4 (p < 0.001), PGA from 2.7 to 0.5 (p < 0.001), LLDAS increasing from 0% to 51.3% (p < 0.001), and flares decreasing from 95.0% to 18.8% (p < 0.001). Glucocorticoid burden also declined, with oral glucocorticoid use falling from 95.0% to 83.8% (p = 0.021), median prednisone dose from 20 mg/day to 5 mg/day (p < 0.001), intravenous methylprednisolone use from 50.0% to 6.3% (p < 0.001), and 63.8% achieving prednisone doses ≤ 7.5 mg/day (p < 0.001). Laboratory improvement included hemoglobin, leukocyte count, lymphocyte count, platelet count, C3, C4, anti-dsDNA, C-reactive protein (CRP), and erythrocyte sedimentation rate (ESR), while serum creatinine did not change significantly (p = 0.904). No serious adverse events were reported. Conclusions: Anifrolumab was associated with significant short-term improvement in clinical and laboratory disease activity, marked steroid sparing, and reduced flare burden in Egyptian patients with moderate-to-severe SLE, with acceptable short-term tolerability.

  • Open Access

    Long non-coding RNA (H19) in patients with spondyloarthritis: association with disease parameters and ultrasonographic findings

    by A. I. El-Zwawy, Eiman Soliman, Eman T. Elsayed, Mai M. Morsy

    Background: Spondyloarthritis is a well-known chronic inflammatory disorder; despite recent advances, its genetic basis remains poorly understood. Recently, long non-coding RNA (H19) was identified to be associated with various human cancers and studied in some autoimmune diseases. Musculoskeletal ultrasound has been shown to have good sensitivity and specificity in detecting enthesitis. The Belgrade Ultrasound Enthesitis Score (BUSES) has recently been proposed as a comprehensive ultrasound enthesitis scoring system for differentiating between individuals with enthesitis associated with spondyloarthritis and those without spondyloarthritis. Aim: The current work aimed to study the role of long non-coding RNA (H19) as a potential biomarker in axial spondyloarthritis and its relationship with the different disease parameters (clinical and laboratory), disease activity, and functional status as well as the relation between long non-coding RNA (H19) and articular manifestations using ultrasonographic assessment of enthesitis. Results: Long non-coding RNA (H19) expression was statistically higher in axial spondyloarthritis patients than controls; there are no statistically significant correlations between long non-coding RNA (H19) relative expression and any of the listed parameters (ESR, CRP, ASDAS-CRP, BASDAI, BASFI, BASMI, BUSES, SPARCC index, mSASSS). As regards the Spearman correlation of Belgrade Ultrasound Enthesitis Score, it showed a statistically significant positive correlation with ASDAS-CRP, BASDAI, and BASMI (p value: 0.002, 0.02, and 0.046, respectively). Conclusion: Both long non-coding RNA (H19) and Belgrade Ultrasound Enthesitis Score have good discriminative ability between patients with axial spondyloarthritis and normal population; this suggests a possible role in early diagnosis for patients with axial spondyloarthritis who do not fulfill ASAS classification criteria. Their role to monitor the disease activity still needs further studies to be established. Musculoskeletal ultrasound is much more accurate in the assessment of enthesis than clinical examination. Further studies are needed to study the correlation between ultrasonographic entheseal scores and activity markers either clinically or laboratory.